Clinical Trial Update: Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities [Phase 1]

View source ↗

Summary

Phase 1 study evaluating multiple doses of HM15136 (Efpegerglucagon) in obese or overweight adults with comorbidities has completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• HM15136 (Efpegerglucagon) (Efpegerglucagon)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Obese With Comorbidities, Overweight With Comorbidities | Phase 1 | Status: COMPLETED | Results posted: 2025-01-27